
Bristol-Myers Squibb Company BMY
$ 58.08
0.03%
Annual report 2025
added 02-11-2026
Bristol-Myers Squibb Company EV - Enterprise Value 2011-2026 | BMY
Annual EV - Enterprise Value Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 184 B | 180 B | 154 B | 211 B | 210 B | 199 B | 210 B | 93.7 B | 121 B | 94.5 B | 119 B | 113 B | 103 B | 81.8 B | 66.2 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 211 B | 66.2 B | 143 B |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.62 | -1.09 % | $ 8.71 B | ||
|
BioNTech SE
BNTX
|
-4.91 B | $ 98.41 | 1.77 % | $ 27.2 B | ||
|
Burford Capital Limited
BUR
|
3.22 B | $ 4.71 | 4.9 % | $ 760 M | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
82.6 M | $ 8.74 | 0.23 % | $ 86.4 M | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | ||
|
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 21.38 | 0.09 % | $ 999 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
493 M | $ 1.56 | 6.12 % | $ 401 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 3.05 | 4.45 % | $ 5.02 M | ||
|
Aquestive Therapeutics
AQST
|
540 M | $ 4.15 | -0.95 % | $ 444 M | ||
|
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 25.09 | 4.02 % | $ 3.19 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
629 M | $ 1.48 | 0.68 % | $ 394 M | ||
|
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B | ||
|
Evogene Ltd.
EVGN
|
-4.88 M | $ 0.82 | 0.02 % | $ 27.9 M | ||
|
AVROBIO
AVRO
|
-35.4 M | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
bluebird bio
BLUE
|
270 M | - | - | $ 546 M | ||
|
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | ||
|
Cabaletta Bio
CABA
|
253 M | $ 3.26 | 1.87 % | $ 328 M | ||
|
Cidara Therapeutics
CDTX
|
9.99 M | - | - | $ 1.41 B | ||
|
Akari Therapeutics, Plc
AKTX
|
79.3 B | $ 4.63 | 9.01 % | $ 312 B | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | ||
|
Baudax Bio
BXRX
|
29.8 M | - | 0.59 % | $ 63 K | ||
|
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B |